Downloads
Abstract
Background: Recent advances in molecular biomedicine have brought targeted therapies that improve treatment results and prolong survival outcomes for metastasis non-small cell lung cancer (NSCLC) patients with fewer adverse events than chemotherapy. This study aims to evaluate the efficacy of the first-generation EGFR-TKI in patients with metastatic NSCLC at the Vietnam National Cancer Hospital.
Method: This was a retrospective and prospective study on 302 patients diagnosed with EGFR-mutated metastatic NSCLC treated with first-line erlotinib at the Vietnam National Cancer Hospital from March 2018 to March 2023.
Results: Disease control rate was 95.4%. Median progression-free survival (PFS) was 17 months, median overall survival (OS) was 35 months. The most common side effect was skin rash, mainly grade 1-2.
Conclusion: First-generation EGFR-TKI resulted in a high disease control rate, promising PFS and OS and was well tolerated.
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2021;71(3):209-249.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA: a cancer journal for clinicians. 2018;68(1):7-30.
Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JH, Beasley MB, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. Journal of thoracic oncology. 2015;10(9):1243-1260.
Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ, Wu Y-L, et al. Lung cancer: current therapies and new targeted treatments. The Lancet. 2017;389(10066):299-311.
Kuan F-C, Kuo L-T, Chen M-C, Yang C-T, Shi C-S, Teng D, et al. Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancers: a systematic review and meta-analysis. British journal of cancer. 2015;113(10):1519-1528.
Lee CK, Davies L, Wu Y-L, Mitsudomi T, Inoue A, Rosell R, et al. Gefitinib or erlotinib vs chemotherapy for EGFR mutation-positive lung cancer: individual patient data metaanalysis of overall survival. JNCI: Journal of the National Cancer Institute. 2017;109(6):djw279.
Socinski MA, Evans T, Gettinger S, Hensing TA, Sequist LV, Ireland B, et al. Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5):e341S-e368S.
Wu Y-L, Zhou C, Liam C-K, Wu G, Liu X, Zhong Z, et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Annals of oncology. 2015;26(9):1883-1889.
Kim ES, Melosky B, Park K, Yamamoto N, Yang JC-H. EGFR tyrosine kinase inhibitors for EGFR mutation positive non-small-cell lung cancer: outcomes in Asian populations. Future Oncology. 2021;17(18):2395-2408.
Lê Thu Hà TVT. Đáp ứng thuốc erlotinib trong điều trị bệnh nhân ung thư phổi không tế bào nhỏ giai đoạn muộn. Tạp chí Y học thực hành. 2016;993:53-55.
| Published | 23-12-2024 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | Vol. 16 No. 6 (2024) | |
| Section | Original article | |
| DOI | 10.38103/jcmhch.16.6.15 | |
| Keywords | Erlotinib, ung thư phổi không tế bào nhỏ, đột biến EGFR Erlotinib, metastatic non-small cell lung cancer, EGFR mutations |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2024 Journal of Clinical Medicine Hue Central Hospital